Without better vaccines it is unlikely that tuberculosis (TB) will ever be eliminated. An
investment of∼€ 560 million is considered necessary to develop a new, effective vaccine in …

BACKGROUND: Tuberculosis (TB) is a major infection with nearly eight million cases
annually worldwide. Although the majority of these cases are in the developing world, TB is …

BACKGROUND: There is a dearth of economic analysis required to support increased
investment in TB in India. This study estimates the costs of TB services from a health …

Objectives To analyze the cost-effectiveness of mass primovaccination of newborns in the
Slovak Republic with BCG vaccine against tuberculosis compared to the cost-effectiveness …

Novel tuberculosis vaccines are in varying stages of pre-clinical and clinical development.
This study seeks to estimate the potential cost-effectiveness of a BCG booster vaccine, while …

SETTING: Mycobacterium bovis bacille Calmette-Guérin (BCG) is provided to all infants born
in Finland. OBJECTIVE: To analyze the cost-effectiveness of universal versus selective BCG …

In the present paper there are reviewed some issues concerning tuberculosis (TB) in
children in Romania comparative to The Republic of Moldova. The data information came …

Background: 4,444 new cases of tuberculosis (TB) were reported in Germany in 2009; of
those, the proportion of multidrug-resistant TB (MDR-TB) cases increased to 2.1%(63 …

Background The burden of childhood tuberculosis remains high globally, largely due to
under-diagnosis. Decentralising childhood tuberculosis diagnosis services to lower health …

Although the total number appears to be decreasing, 7,886 new cases of tuberculosis (TB)
were reported in Germany in 2001. Previous American publications reveal considerable …